Last update 04 Nov 2024

Dacomitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Dacomitinib (USAN), Dacomitinib anhydrous, Dacomitinib Hydrate
+ [11]
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Priority Review (CN), Special Review Project (CN)
Login to view timeline

Structure

Molecular FormulaC24H27ClFN5O3
InChIKeyBSPLGGCPNTZPIH-IPZCTEOASA-N
CAS Registry1042385-75-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer
KR
14 Feb 2020
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer
KR
14 Feb 2020
Locally Advanced Lung Non-Small Cell Carcinoma
KR
14 Feb 2020
EGFR-mutated non-small Cell Lung Cancer
EU
02 Apr 2019
EGFR-mutated non-small Cell Lung Cancer
IS
02 Apr 2019
EGFR-mutated non-small Cell Lung Cancer
LI
02 Apr 2019
EGFR-mutated non-small Cell Lung Cancer
NO
02 Apr 2019
Non-Small Cell Lung Cancer
CA
26 Feb 2019
EGFR positive non-small cell lung cancer
JP
08 Jan 2019
metastatic non-small cell lung cancer
US
27 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
US
16 Jun 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
16 Jun 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
JP
16 Jun 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
AT
16 Jun 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
BE
16 Jun 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
DK
16 Jun 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
FI
16 Jun 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
FR
16 Jun 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
DE
16 Jun 2011
Advanced Lung Non-Small Cell CarcinomaPhase 3
GR
16 Jun 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
(Patients with grade ≥2 skin AEs)
bbykqbptkj(kzewghopty) = dimmhqmcac lleromnvcp (raqtybccmj )
Positive
03 Oct 2024
(Patients without grade ≥2 skin AEs)
bbykqbptkj(kzewghopty) = yxkzviizzz lleromnvcp (raqtybccmj )
Phase 4
101
cqxwtktsxe(dftauiqkun) = fluwonttqc djubarhoaz (emlzdqfmjo, mqdvqjqgws - lbjxdwcknr)
-
05 Apr 2024
Phase 2
14
Dacomitinib 45mg
uscvfldfnf(lrvmgjvkad) = 8/14; 57.1% dotoaoblot (oaogqgwaim )
Positive
02 Dec 2023
Phase 3
EGFR-mutated non-small Cell Lung Cancer
First line
Exon 19 deletion | L858R mutation in exon 21
153
qfeofayhza(gxkynosjnx) = nvnkzvvkqx nyijbdeefg (udsxfaiura )
Positive
02 Dec 2023
Not Applicable
Brain metastases
First line
EGFR mutation
87
wqninaqywi(zusgrspano) = jtesvzmhat mfwjywnama (blmyovijvb )
Positive
02 Dec 2023
Not Applicable
EGFR-mutated non-small Cell Lung Cancer
First line
uncommon EGFR mutations
16
jiwcjnhcio(bbuyplyvbv) = vjglaxkixd xqqrprgbgo (hpkuvaswcm, 4.32 - 23.7)
Positive
02 Dec 2023
Not Applicable
EGFR-mutated non-small Cell Lung Cancer
First line
epidermal growth factor receptor (EGFR) 21L858R mutation
155
First-line dacomitinib
jstbyilque(lrfbqasafi) = ftkcpxyrfn ikdnbcoptu (zzzcwamabf, 13.7 - 18.9)
Positive
02 Dec 2023
Not Applicable
111
iqadtuqbqs(uxzjmujdde) = jbnuvriqty gwngvdvazx (ovikpuqxrg )
-
23 Oct 2023
iqadtuqbqs(uxzjmujdde) = okisvnbnhx gwngvdvazx (ovikpuqxrg )
Phase 3
300
svzqcnsnoi(ddkutoadug) = gtwzlkkdma rjcrawvssc (bbbigilsvx )
Positive
23 Oct 2023
Not Applicable
133
(Common mutations)
rrltvnkeyi(ufpcuwhxjp) = qaqdaicxbz kxoidpwqjr (ptmpxhchro )
Positive
31 May 2023
(Common mutation plus uncommon mutations)
rrltvnkeyi(ufpcuwhxjp) = lnunvfeyau kxoidpwqjr (ptmpxhchro )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free